MIT chemical engineers have developed a new sensor that lets them see inside cancer cells and determine whether the cells are responding to a particular type of chemotherapy drug.
The sensors, which detect hydrogen peroxide inside human cells, could help researchers identify new cancer drugs that boost levels of hydrogen peroxide, which induces programmed cell death. The sensors could also be adapted to screen individual patients’ tumors to predict whether such drugs would be effective against them.
“The same therapy isn’t going to work against all tumors,” says Hadley Sikes, an associate professor of chemical engineering at MIT. “Currently there’s a real dearth of quantitative, chemically specific tools to be able to measure the changes that occur in tumor cells versus normal cells in response to drug treatment.”
Sikes is the senior author of the study, which appears in the Aug. 7 issue of Nature Communications. The paper’s first author is graduate student Troy Langford; other authors are former graduate students Beijing Huang and Joseph Lim and graduate student Sun Jin Moon.
Tracking hydrogen peroxide
Cancer cells often have mutations that cause their metabolism to go awry and produce abnormally high fluxes of hydrogen peroxide. When too much of the molecule is produced, it can damage cells, so cancer cells become highly dependent on antioxidant systems that remove hydrogen peroxide from cells.
Drugs that target this vulnerability, which are known as “redox drugs,” can work by either disabling the antioxidant systems or further boosting production of hydrogen peroxide. Many such drugs have entered clinical trials, with mixed results.
“One of the problems is that the clinical trials usually find that they work for some patients and they don’t work for other patients,” Sikes says. “We really need tools to be able to do more well-designed trials where we figure out which patients are going to respond to this approach and which aren’t, so more of these drugs can be approved.”
To help move toward that goal, Sikes set out to design a sensor that could sensitively detect hydrogen peroxide inside human cells, allowing scientists to measure a cell’s response to such drugs.
Existing hydrogen peroxide sensors are based on proteins called transcription factors, taken from microbes and engineered to fluoresce when they react with hydrogen peroxide. Sikes and her colleagues tried to use these in human cells but found that they were not sensitive in the range of hydrogen peroxide they were trying to detect, which led them to seek human proteins that could perform the task.
Through studies of the network of human proteins that become oxidized with increasing hydrogen peroxide, the researchers identified an enzyme called peroxiredoxin that dominates most human cells’ reactions with the molecule. One of this enzyme’s many functions is sensing changes in hydrogen peroxide levels.
Langford then modified the protein by adding two fluorescent molecules to it — a green fluorescent protein at one end and a red fluorescent protein at the other end. When the sensor reacts with hydrogen peroxide, its shape changes, bringing the two fluorescent proteins closer together. The researchers can detect whether this shift has occurred by shining green light onto the cells: If no hydrogen peroxide has been detected, the glow remains green; if hydrogen peroxide is present, the sensor glows red instead.
The researchers tested their new sensor in two types of human cancer cells: one set that they knew was susceptible to a redox drug called piperlongumine, and another that they knew was not susceptible. The sensor revealed that hydrogen peroxide levels were unchanged in the resistant cells but went up in the susceptible cells, as the researchers expected.
Sikes envisions two major uses for this sensor. One is to screen libraries of existing drugs, or compounds that could potentially be used as drugs, to determine if they have the desired effect of increasing hydrogen peroxide concentration in cancer cells. Another potential use is to screen patients before they receive such drugs, to see if the drugs will be successful against each patient’s tumor. Sikes is now pursuing both of these approaches.
“You have to know which cancer drugs work in this way, and then which tumors are going to respond,” she says. “Those are two separate but related problems that both need to be solved for this approach to have practical impact in the clinic.”
Receive an email update when we add a new CANCER THERAPY article.
The Latest on: Cancer therapy
via Google News
The Latest on: Cancer therapy
- Toddler Battling Cancer Receives Rock Star Treatment At Allen Hockey Game on January 11, 2019 at 9:15 pm
A three-year-old battling cancer received the rock star treatment at Friday night’s Allen American’s game. Wyatt Brooks was born with various medical conditions. He has down syndrome and went through ... […]
- Kyle Vericella: St. Lucie County teenager diagnosed with brain cancer, family hoping for community support to help visit him during treatment on January 11, 2019 at 7:14 pm
ST LUCIE COUNTY, Fla. — A St. Lucie County teenager is gearing up for the fight for his life. 18-Year-Old Kyle Vericella was diagnosed days before Christmas with an aggressive brain tumor, called Anap... […]
- Lilly eyes more cancer deals, but wary of CAR-T, gene therapy on January 11, 2019 at 11:47 am
(Reuters) - Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology this week, but it plans to remain on the sidelines when it comes to two ... […]
- Research to advance cancer therapy on January 11, 2019 at 10:21 am
Research led by Suresh Alahari, Ph.D., the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health New Orleans School of Medicine, has found a new role for a protein discovered ... […]
- Justice Ruth Bader Ginsburg will return to work, no further medical treatment needed on January 11, 2019 at 10:05 am
Doctors removed a portion of her lung on December 21 after cancerous nodules were detected. Ruth Bader Ginsburg cancer recovery 'is on track,' no further treatment needed Jan. 11, 201902:22 "Post-surg... […]
- VISTA checkpoint implicated in pancreatic cancer immunotherapy resistance on January 11, 2019 at 8:20 am
Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective ... […]
- ASU researchers address a primary cause of treatment failure for pancreatic cancer on January 11, 2019 at 6:47 am
As the second leading cause of death worldwide, cancer is a focal point in both clinical research and health care fields, but not all cancers are created equal. While some cancers are now much less de... […]
- Hormone Therapy for Breast Cancer (Fact Sheet) on January 10, 2019 at 1:09 pm
Hormones are substances that function as chemical messengers in the body. They affect the actions of cells and tissues at various locations in the body, often reaching their targets through the bloods... […]
- Collaboration between NMSU and UNM Cancer Center could lead to new skin cancer treatment on January 10, 2019 at 12:06 pm
From left: professors Eric Prossnitz of the University of New Mexico Department of Internal Medicine and Jeffrey Arterburn of New Mexico State University's Department of Chemistry and Biochemistry dis... […]
via Bing News